TA-01 inhibitors inhibit cardiac development when applied at 5 μM. TA-01 shows an almost complete inhibition of cardiogenesis when applied at 5 μM. TA-01 shows reduced expression of all tested mesoderm markers and the pre-cardiac marker Isl-1.
| Cell Experiment | |
|---|---|
| Cell lines | Human pluripotent stemcell lines HES-3 and H7 |
| Preparation method | Human pluripotent stemcell lines HES-3 and H7 were seeded at 2.5 × 106 cells/12-ULA well in BSFS medium with cell line optimized concentrations of CHIR99021 for 24 h (Supplemental Fig. S7). Thereafter the 2,4,5-trisubstituted azoles or IWP-2 or IWR-1 were added at a concentration of 5 μM (2.5 μM for IWR-1) either from 1-8 days or from 4-8 days. Dissociated EBs showed an average of 50–60% NKX2-5+ cells on day 11 when either 2,4,5-trisubstituted azoles, IWP-2 and IWR-1 were applied from 4-8 days i.e. at the post mesoderm stage. In comparison to premesoderm treatment only HES-3 showed high cardiomyocyte expansion fold with SB203580 (days 1-8) (Fig. 3A). To confirm that 2,4,5-trisubstituted azoles had no negative impact on cell viability, we analyzed the cell growth kinetics. EBs treated with IWP-2 and IWR-1 generated significantly fewer cells compared to 2,4,5-trisubstituted azoles in both cell lines (Fig. 3A). Metabolismrates of EBs measured with MTT showed an increase with TA-01 but not with IWR-1 and IWP-2 during the compound induction period. |
| Concentrations | 5 μM |
| Incubation time | - |
| Animal Experiment | |
|---|---|
| Animal models | |
| Formulation | |
| Dosages | |
| Administration | |
| Molecular Weight | 351.32 |
| Formula | C20H12F3N3 |
| CAS Number | 1784751-18-3 |
| Solubility (25°C) | DMSO ≥ 30 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Casein Kinase Products |
|---|
| ON 108600
ON 108600 is an inhibitor of CK2 (Casein Kinase2)/TNIK/DYRK1 with IC50 values of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK, respectively. 0.005 μM. It has anti-tumor activity. |
| (R)-DRF053 dihydrochloride
(R)-DRF053 dihydrochloride is a potent inhibitor of casein kinase 1 (CK1), CDK1/cyclin B, and CDK5/p25, with IC50s of 14 nM, 220 nM, and 80 nM, respectively.(R)-DRF053 dihydrochloride prevented the production of CK1-dependent amyloid-β in cellular models. In addition, (R)-DRF053 dihydrochloride prevented the production of CK1-dependent amyloid-β in cell models. |
| Casein kinase 1δ-IN-5
Casein kinase 1δ-IN-5 is a potent and selective protein kinase CK-1δ inhibitor with an IC50 of 47 nM, which has neuroprotective and anti-inflammatory properties in vitro. It has neuroprotective and anti-inflammatory properties in vitro. It can be used in studies related to neurodegenerative diseases. |
| CK2-IN-1
CK2-IN-1 is a CK2 inhibitor with an IC50 value of 150 nM. |
| SR-1277
SR-1277 is a potent, selective and ATP-competitive CK1δ/ε inhibitor with IC50 values of 49 nM and 260 nM, respectively.In addition, SR-1277 inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3, and CDK9/cyclin K with IC50 values of 305 nM, 1340 nM, 311 nM, and 109 nM, respectively. 1340 nM, 311 nM and 109 nM, respectively, and can be used in cancer research. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
